Exposure to Neurotoxins as Risk Factors for ALS
NCT00340301 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 397
Last updated 2019-01-25
Summary
Chemicals called neurotoxins can harm the nervous system. Amyotrophic lateral sclerosis (ALS) is a progressive disease affecting movement. Researchers have studied many possible causes of ALS, including injury, diet, and exposure to chemicals, but these studies were inconclusive.
The purpose of this study was to determine whether exposure to lead or other neurotoxins can contribute to ALS. The study also evaluated lifestyle and dietary patterns. The study was completed in 1994-1996.
One hundred eighty-two participants took part in this study 110 patients with ALS and 72 who did not have ALS. Each completed a questionnaire concerning lifestyle, diet, and residential, job, and medical history. Participants contributed 50 cc of blood, used to measure lead, as well as clippings of their toenails, used to measure mercury and other metals. They then underwent an XRF test (an X-ray procedure) to measure the level of lead in their shinbones and knees. Genes related to ALS or susceptibility to lead exposure were also evaluated.
Conditions
Sponsors & Collaborators
-
National Institute of Environmental Health Sciences (NIEHS)
lead NIH
Principal Investigators
-
Freya Kamel, Ph.D. · National Institute of Environmental Health Sciences (NIEHS)
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-06-03
- Completion
- 2019-01-23
Countries
- United States
Study Locations
More Related Trials
-
Determining the Safety of L-serine in ALS
NCT01835782 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS)
NCT04454892 ·Status: RECRUITING
-
Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS
NCT05349721 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT03160898 ·Status: COMPLETED ·Phase: PHASE2
-
New Therapeutic Strategy in ALS Based on Metabolic Status and Associated Metabolic Pathways.
NCT03984708 ·Status: COMPLETED ·Phase: NA
-
Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)
NCT01091142 ·Status: COMPLETED ·Phase: PHASE1
-
Influence of Olfacto-gustatory Sensoriality on the Nutritional Status of Patients With Amyotrophic Lateral Sclerosis
NCT06608004 ·Status: RECRUITING
-
Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation
NCT02794857 ·Status: COMPLETED ·Phase: PHASE2
-
Mitochondrial Functions and Oxidative Stress in ALS Patients
NCT00331812 ·Status: UNKNOWN
-
Measurement and Impact of Physical Impairment in Amyotrophic Lateral Sclerosis: Use of Digital Technologies - A Precision ALS Project
NCT06820008 ·Status: RECRUITING
-
ALS Research Collaborative
NCT06885918 ·Status: RECRUITING
-
Environmental Exposure and Neurological Diseases Questionnaire
NCT02916966 ·Status: COMPLETED
-
Amyotrophic Lateral Sclerosis (ALS) Families Project
NCT03865420 ·Status: RECRUITING
-
A Registered Cohort Study on Amyotrophic Lateral Sclerosis
NCT04008329 ·Status: RECRUITING
-
Cistanche Total Glycosides for Amyotrophic Lateral Sclerosis: A Randomized Control Trial (RCT) Study Assessing Clinical Response
NCT00753571 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of Deep Cervical Lymph Node-vein Bypass Surgery in ALS Amyotrophic Lateral Sclerosis
NCT06351735 ·Status: NOT_YET_RECRUITING
-
A Study to Explore the Role of Gut Flora in ALS
NCT04150809 ·Status: WITHDRAWN
-
Explore Neuroprotective Effect of Lipoic Acid in Amyotrophic Lateral Sclerosis
NCT04518540 ·Status: UNKNOWN ·Phase: NA
-
Longitudinal Assessment of Autonomic and Sensory Nervous System in ALS
NCT05747937 ·Status: RECRUITING ·Phase: NA
-
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
NCT02611674 ·Status: COMPLETED
-
ALS Reversals - Lunasin Regimen
NCT02709330 ·Status: COMPLETED ·Phase: PHASE2
-
Amyotrophic Lateral Sclerosis: a New Paradigm
NCT03073239 ·Status: COMPLETED
-
Neurofilament Light Chain in Amyotrophic Lateral Sclerosis
NCT06201650 ·Status: RECRUITING
-
Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS)
NCT00231140 ·Status: TERMINATED ·Phase: PHASE2
-
Spinal Interneuron Excitability in ALS
NCT02429492 ·Status: COMPLETED ·Phase: NA